Key points are not available for this paper at this time.
PURPOSE: Ac)-labelled FAPI-46 in pancreatic cancer models. METHODS: Ac]FAPI-46. Tumour sizes and body weights were followed. RESULTS: Ac]FAPI-46. CONCLUSION: This study suggested the possible application of FAPI radioligand therapy in FAP-expressing pancreatic cancer. Further evaluation is necessary to find the best radionuclide with shorter half-life, as well as the combination with therapies targeting tumour cells directly.
Liu et al. (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: